Moderna (MRNA) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Moderna (MRNA) has outperformed Bio-Techne (TECH) over the past year, gaining 618.7% versus a gain of 22.5%. Over five years, MRNA leads with a -40.0% price change compared with -41.7% for TECH. Moderna is the larger company by market cap ($78.44 billion vs $11.37 billion), about 6.9 times the size, while Bio-Techne is growing revenue faster (-0.4% vs -39.9%).
Bio-Techne pays a dividend yielding 0.44%, while Moderna does not currently pay one. Bio-Techne converts more of its revenue into profit, with a net margin of 15.0% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | TECH |
|---|---|---|
| Share price | $196.48 | $72.53 |
| Market cap | $78.44B | $11.37B |
| 1-day change | +4.81% | +0.14% |
| YTD return | +566.26% | +23.33% |
| 1-year return | +618.65% | +22.54% |
| 5-year return | -39.96% | -41.75% |
| P/E ratio (TTM) | — | 62.53 |
| Forward P/E | — | 31.36 |
| EPS (TTM) | $-7.98 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $1.94B | $1.22B |
| Revenue growth (YoY) | -39.93% | -0.38% |
| Net income (latest FY) | $-2.82B | $181.86M |
| Gross margin | 55.35% | 65.77% |
| Operating margin | -158.13% | 20.73% |
| Net margin | -145.16% | 14.97% |
| 52-week high | $212.22 | $72.69 |
| 52-week low | $22.28 | $43.20 |
| Distance from 52-week high | -7.42% | -0.22% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -38.42% | -2.80% |
| Average volume | 17.31M | 3.08M |
| Shares outstanding | 399.24M | 156.82M |
| Employees | 4,700 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 6.9 times larger than Bio-Techne by market value ($78.44B vs $11.37B).
- MRNA has outperformed TECH by 596.1 percentage points over the past year.
- Bio-Techne is more profitable, keeping 15.0 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Bio-Techne grew revenue faster in its latest fiscal year (-0.38% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
MRNA vs TECH FAQ
Which is bigger, Moderna or Bio-Techne?
Moderna (MRNA) is larger, with a market capitalization of $78.44B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, MRNA or TECH?
MRNA returned +618.65% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Moderna or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Moderna does not currently pay a regular dividend.
Are Moderna and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.